|Biotech Due Diligence||
Cancer has been an elusive target for Isis Pharmaceuticals ISIS and their antisense drug candidates over the years, resulting in some spectacular failures in the past. In addition to the impending phase 3 prostate cancer data from partners OncoGenex $OGXI and Teva Pharmaceuticals $TEVA, Isis also has a growing roster of early stage cancer assets, a number of which now are included in a preferred partner option arrangement with AstraZeneca $AZN.
See below for recent comments from Teva Pharmaceuticals $TEVA and Baxter International $BAX relevant to Momenta Pharmaceuticals $MNTA - specifically their generic COPAXONE program for MS and their biosimilars partnership, respectively.
Antares Pharma $ATRS has a number of product partnerships with Teva Pharmaceuticals $TEVA based around a series of parenteral injection devices. These deals have been shrouded in secrecy and also littered with delays over the years. Recently though Teva briefly addressed the Epi-pen program on their 1q-2013 conference call (excerpt via SeekingAlpha).
Just curious to know your confidence level in the FDA's ability to approve EpiPen, an AB-rated EpiPen in 2015?
So, just to your second on question on EpiPen, I will let you know we had a settlement with Mylan and we have an entry date in 2015. The trial Is progressing well.
This post features comments from the Teva Pharmaceuticals $TEVA year-end 2012 earnings conference call that are relevant to companies covered here at BiotechDueDiligence.
As usual the discussion centers COPAXONE for multiple sclerosis, which Momenta Pharmaceutical $MNTA and partner Sandoz (Novartis $NVS) are seeking approval for a generic version of.
MNTA and biosimilars - notes from other biotech/pharma conference calls
Other blog posts related to TEVA and MNTA
For the moment, this will be the final installment of the BiotechDueDiligence AACR Annual Meeting preview..thanks for sticking with us. As always, see below for another collection of presentations from biotech companies covered on the website.
Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Preview Part 4 (ASTX, ARQL, BPAX)
Preview Part 5 (TKMR, EXEL, PCYC, IMMU, VRTX)
Preview Part 6 (CRIS INFI ISIS CLDX LGND PCYC)